Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 8CNS 1

Conditions

von Hippel-Lindau Disease 2Pheochromocytoma 2Paraganglioma 2Carcinoma, Renal Cell 2Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Kidney Neoplasms 1Hemangioblastoma 1Glioblastoma 1Adenoma, Islet Cell 1

Interventions

Filgrastim 7Carboplatin 5Thiotepa 3Temozolomide 3Peripheral Blood Stem Cell Transplantation 3Ifosfamide 3sargramostim 2motexafin gadolinium 2etoposide phosphate 2Sunitinib 2Radiosurgery 2Paclitaxel 2Melphalan 2Immunohistochemistry 2Granulocyte Colony-Stimulating Factor 2Gene Expression Profiling 2Etoposide 2Busulfan 2Amplified Fragment Length Polymorphism Analysis 2Amifostine 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1tanespimycin 1pentetreotide 1pembrolizumab 1oblimersen 1liposomal doxorubicin 1ixabepilone 1guadecitabine 1gallium Ga 68 dotatate 1erythromycin propionate-N-acetylcysteinate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × belzutifan × CNS × Clear all
NCT02974738 2025-07-10

MK-6482-001

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1 Active not recruiting
120 enrolled
CNSGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Kidney Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡